Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark.
As diagnostic laboratories evolve to meet growing workloads in an increasingly challenging environment, the cobas e 801 module offers high value through its flexibility, which allows for the efficient use of existing resources such as space, infrastructure and personnel. The module is designed for maximum consolidation at a high throughput, continuous operation and, at the same time, it reduces the amount of waste generated, for more environmentally friendly testing.
“Today, laboratories need to deliver more diagnostic tests than ever before, while in many cases their resources are constrained” said Roland Diggelmann, CEO Roche Diagnostics. “The cobas e 801 module is an important part of Roche’s connected laboratory solutions that allows laboratories to test efficiently and to sustainably grow their testing capacity.”
The cobas e 801 module almost doubles the currently available immunochemistry testing capacity on the same footprint. The system only requires a low sample volume, offers an extensive assay menu and delivers fast, reliable and consistent patient results across systems. This benefits patients and healthcare professionals by providing the accurate and timely results needed to make the correct treatment decisions.